This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Monro, A. Articles by Mordenti, J. Search for Related Content PubMed PubMed Citation Articles by Monro, A. Articles by Mordenti, J. Social Bookmarking                         What's this?

Expression of Exposure in Negative Carcinogenicity Studies: Dose/Body Weight, Dose/Body Surface Area, or Plasma Concentrations?

Pfizer Central Research, Groton, Connecticut 06340

Joyce Mordenti

Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, California 94080

Evaluation of positive findings in a rodent carcinogenicity study and the subsequent extrapolation to humans is based on chemical structure, mutagenicity, pharmacology, hormone changes, chronic toxicity, and the nature of the tumors induced. For negative studies, adequacy of exposure may become an issue. The use of plasma concentrations as a metric for exposure assumes that each species responds in a similar manner to a given concentration; data are now available that demonstrate that this is not generally true for carcinogenicity. The use of the body surface area metric (i.e., mg/m²) is a special case of interspecies allometric scaling (i.e., W^0.67). For a chemical to be amenable to such scaling in toxicology, it must satisfy 3 criteria: (a) the concentration-time profile of the putative toxicant at the site of action must be governed by a scalable pharmacokinetic process (e.g., glomerular filtration); (b) the mechanism of action and the susceptibility of each species to a given systemic exposure must be the same and, for example, be independent of lifespan, cellular repair mechanism/rate, and so forth; and (c) the biological response must depend only on size (e.g., not on race, strain, gender, age, or parity). Carcinogens rarely, if ever, meet these criteria. An empirical analysis of carcinogenic potency data in rodents and in humans shows that, in general, exposure is best expressed in terms of mg/kg body weight.

Key Words: Allometric scaling • dose metrics • mice • pharmacokinetics • rats

Toxicologic Pathology, Vol. 23, No. 2, 187-198 (1995)
DOI: 10.1177/019262339502300213


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J.-P. H. T. M. Ploemen, H. Kramer, E. I. Krajnc, and I. Martin The Use of Toxicokinetic Data in Preclinical Safety Assessment: A Toxicologic Pathologist Perspective Toxicol Pathol, October 1, 2007; 35(6): 834 - 837. [Abstract] [Full Text] [PDF]

				L. A Dethloff, M. J Graziano, E. Goldenthal, A. Gough, and F. A de la Iglesia Perspective on the carcinogenic potential of phenytoin based on rodent tumor bioassays and human epidemiological data Human and Experimental Toxicology, April 1, 1996; 15(4): 335 - 348. [Abstract] [PDF]